WLF Appeals Court Decision Leaves Free Speech Question Open
Executive Summary
FDA's ability to introduce sponsor dissemination of off-label reprints as evidence in enforcement action litigation may be the next item open for constitutional questioning, following the Feb. 11 dismissal of Washington Legal Foundation v. Henney by the Washington D.C. appeals court.
You may also be interested in...
FDA’s TV Ad Review Is Unconstitutional, PhRMA Says, Or Maybe Should Be A Reg
A draft guidance that outlines six categories of drug ads FDA wants submitted for prior review is a violation of advertisers’ free speech rights, the industry group argues. Other comments float a storyboard compromise.
Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content